Align with these studies, glioblastoma-derived EVs enriched with immunosuppressive molecules, including FasL, CTLA-4, CD39, and CD73 suppress the expression of NKG2D in NK cells, thereby mitigating NK cell activation [102]. The gene discussed is CTLA4; the disease is glioblastoma.